Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

Open access
Beavis, Paul A., Henderson, Melissa A., Giuffrida, Lauren, Mills, Jane K., Sek, Kevin, Cross, Ryan S., Davenport, Alexander J., John, Liza B., Mardiana, Sherly, Slaney, Clare Y., Johnstone, Ricky W., Trapani, Joseph A., Stagg, John, Loi, Sherene, Kats, Lev, Gyorki, David, Kershaw, Michael H., Darcy, Phillip K. · 2017 · Journal of Clinical Investigation

Abstract

Chimeric antigen receptor (CAR) T cells have been highly successful in treating hematological malignancies, including acute and chronic lymphoblastic leukemia. However, treatment of solid tumors using CAR T cells has been largely unsuccessful to date, partly because of tumor-induced immunosuppressive mechanisms, including adenosine production. Previous studies have shown that adenosine generated by tumor cells potently inhibits endogenous antitumor T cell responses through activation of adenosine 2A receptors (A2ARs). Herein, we have observed that CAR activation resulted in increased A2AR expression and suppression of both murine and human CAR T cells. This was reversible using either A2AR antagonists or genetic targeting of A2AR using shRNA. In 2 syngeneic HER2+ self-antigen tumor models, we found that either genetic or pharmacological targeting of the A2AR profoundly increased CAR T cell efficacy, particularly when combined with PD-1 blockade. Mechanistically, this was associated with increased cytokine production of CD8+ CAR T cells and increased activation of both CD8+ and CD4+ CAR T cells. Given the known clinical relevance of the CD73/adenosine pathway in several solid tumor types, and the initiation of phase I trials for A2AR antagonists in oncology, this approach has high translational potential to enhance CAR T cell efficacy in several cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci89455

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 325

Metadata

Authors
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., Johnstone, R. W., Trapani, J. A., Stagg, J., Loi, S., Kats, L., Gyorki, D., Kershaw, M. H., & Darcy, P. K.
Venue
Journal of Clinical Investigation
Published
2017-02-06
Volume
127
Issue
3
Pages
929-941
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2584913109
Cited by
325
References
64
FWCI
13.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. https://app.cochat.ai/papers/10.1172/jci89455
The paper
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., Johnstone, R. W., Trapani, J. A., Stagg, J., Loi, S., Kats, L., Gyorki, D., Kershaw, M. H., & Darcy, P. K. (2017). Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation. https://doi.org/10.1172/jci89455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.